EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis

Journal of Hepatology

Volumn 53, Issue 3, 2010, Pages 397-417

  Ginès, Pere ^a   Angeli, Paolo ^a   Lenz, Kurt ^a   Møller, Søren ^a   Moore, Kevin ^a   Moreau, Richard ^a   Merkel, Carlo ^a   Larsen, Helmer Ring ^a   Bernardi, Mauro ^a   Garcia Tsao, Guadalupe ^a   Hayes, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; AMILORIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFOTAXIME; CIPROFLOXACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; MEZLOCILLIN; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OCTREOTIDE; OFLOXACIN; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; RUFLOXACIN; SATAVAPTAN; SODIUM; SPIRONOLACTONE; TERLIPRESSIN; TOBRAMYCIN; TOLVAPTAN; UNINDEXED DRUG;

ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EDEMA; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; MUSCLE CRAMP; NEPHROTOXICITY; PARACENTESIS; PERITONEUM VEIN SHUNT; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SODIUM RETENTION; SODIUM URINE LEVEL; SYMPTOM; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT INDICATION; TREATMENT OUTCOME; WATER RETENTION;

EID: 77955850168     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.05.004     Document Type: Article

References (229)

1. P. Gins, E. Quintero, and V. Arroyo Compensated cirrhosis: natural history and prognostic factors Hepatology 7 1987 122 128
2. C. Ripoll, R. Groszmann, and G. Garcia-Tsao Hepatic venous gradient predicts clinical decompensation in patients with compensated cirrhosis Gastroenterology 133 2007 481 488
3. R.W. Schrier, V. Arroyo, and M. Bernardi Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8 1988 1151 1157
4. S. Møller, and J.H. Henriksen The systemic circulation in cirrhosis P. Gins, V. Arroyo, J. Rodés, R.W. Schrier, Ascites and renal dysfunction in liver disease 2005 Blackwell Malden 139 155
5. J.H. Henriksen, and S. Møller Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: local factors in the formation of ascites P. Gins, V. Arroyo, J. Rodés, R.W. Schrier, Ascites and renal dysfunction in liver disease 2005 Blackwell Malden 174 185
6. P. Tandon, and G. Garcia-Tsao Bacterial infections, sepsis, and multiorgan failure in cirrhosis Semin Liver Dis 28 2008 26 42
7. M. Guevara, A. Cárdenas, J. Uriz, and P. Gins Prognosis in patients with cirrhosis and ascites P. Gins, V. Arroyo, J. Rodés, R.W. Schrier, Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment 2005 Blackwell Malden 260 270
8. B.A. Runyon Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) Management of adult patients with ascites due to cirrhosis Hepatology 39 2004 841 855
9. B.A. Runyon, A.A. Montano, and E.A. Akriviadis The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites Ann Intern Med 117 1992 215 220
10. A. Rimola, G. Gracia-Tsao, and M. Navasa Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club J Hepatol 32 2000 142 153
11. K.P. Moore, F. Wong, and P. Gins The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club Hepatology 38 2003 258 266
12. J. Llach, P. Gins, and V. Arroyo Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites Gastroenterology 94 1988 482 487
13. L. Caregaro, F. Menon, and P. Angeli Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis Arch Intern Med 154 1994 201 205
14. D.M. Heuman, S.G. Abou-assi, and A. Habib Persistent ascites and low sodium identify patients with cirrhosis and low MELD score who are at high risk for early death Hepatology 40 2004 802 810
15. H. Ring-Larsen, J.H. Henriksen, and C. Wilken Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture Br Med J 292 1986 1351 1353 (Pubitemid 16081812)
16. A. Gatta, P. Angeli, L. Caregaro, F. Menon, D. Sacerdoti, and C. Merkel A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients with ascites Hepatology 14 1991 231 236
17. M. Bernardi, G. Laffi, and M. Salvagnini Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content Liver 13 1993 156 162
18. A. Gauthier, V.G. Levy, and A. Quinton Salt or not salt in the treatment of cirrhotic ascites: a randomized study Gut 27 1986 705 709
19. P. Angeli, A. Gatta, and L. Caregaro Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance Eur J Clin Invest 20 1990 111 117
20. P. Angeli, E. De Bei, and M. Dalla Pria Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention Hepatology 15 1992 651 654
21. M. Bernardi, D. Servadei, and F. Trevisani Importance of plasma aldosterone concentration on natriuretic effect of spironolactone in patients with liver cirrhosis and ascites Digestion 31 1985 189 193
22. R.M. Pérez-Ayuso, V. Arroyo, and R. Planas Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites Gastroenterology 84 1984 961 968
23. P. Angeli, M. Dalla Pria, and E. De Bei Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites Hepatology 19 1994 72 79
24. P. Angeli, S. Fasolato, and E. Mazza Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial Gut 59 2010 98 104
25. J. Santos, R. Planas, and A. Pardo Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety J Hepatol 39 2003 187 192
26. M. Bernardi Optimum use of diuretics in managing ascites in patients with cirrhosis Gut 59 2010 10 11
27. L.S. Shear, S. Ching, and G.J. Gabuzda Compartimentalization of ascites and edema in patients with cirrhosis N Engl J Med 282 1970 1391 1395
28. G. Marchesini, G.P. Bianchi, and P. Amodio Factors associated with poor health-related quality of life of patients with cirrhosis Gastroenterology 120 2001 170 178
29. P. Angeli, G. Albino, and P. Carraro Cirrhosis and muscle cramps: evidence of a causal relationship Hepatology 23 1996 264 273
30. P. Gins, V. Arroyo, and E. Quintero Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study Gastroenterology 92 1987 234 241
31. P. Gins, L.V. Tito, and V. Arroyo Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology 94 1988 1493 1502
32. F. Salerno, S. Badalamenti, and P. Incerti Repeated paracentesis and i.v. albumin infusion to treat "tense ascites" in cirrhotic patients: a safe alternative therapy J Hepatol 5 1987 102 108
33. E. Fassio, R. Terg, G. Landeira, R. Abecasis, M. Salemne, and A. Podesta Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study J Hepatol 14 1992 310 316
34. S.K. Acharya, S. Balwinder, and A.K. Padhee Large-volume paracentesis and intravenous dextran to treat tense ascites J Clin Gastroentrol 14 1992 31 35
35. R. Sol, M.C. Vila, and M. Andreu Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study J Hepatol 20 1994 282 288
36. A. Gins, G. Fernandez-Esparrach, and A. Monescillo Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis Gastroenterology 111 1996 1002 1010
37. I. Pache, and M. Bilodeau Severe hemorrhage following abdominal paracentesis for ascites in patients with liver disease Aliment Pharmacol Ther 21 2005 525 529
38. M. Pozzi, G. Osculati, and G. Boari Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites Gastroenterology 106 1994 709 719
39. L. Ruiz del Arbol, A. Monescillo, and W. Jimenez Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis Gastroenterology 113 1997 579 586
40. J. Sola-Vera, J. Miñana, and E. Ricart Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites Hepatology 37 2003 1147 1153
41. R. Moreau, D.C. Valla, and I. Durand-Zaleski Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail Liver Int 26 2006 46 54
42. M.Z. Panos, K. Moore, P. Vlavianos, J.B. Chambers, and J.V. Anderson Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size Hepatology 11 1990 662 667
43. F.M. Brunkhorst, C. Angel, and F. Bloos Intensive insulin therapy and pentastarch resuscitation in severe sepsis N Engl J Med 358 2008 125 139
44. C. Christidis, F. Mal, and J. Ramos Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions J Hepatol 35 2001 726 732
45. G. Fernández-Esparrach, M. Guevara, and P. Sort Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo J Hepatol 26 1997 614 620
46. C.H. Lin, F.Y. Shih, M.H. Ma, W.C. Chiang, C.W. Yang, and P.C. Ko Should bleeding tendency deter abdominal paracentesis? Dig Liver Dis 37 2005 946 951
47. T.D. Boyer, and T.B. Reynolds Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease Gastroenterology 77 1979 215 222
48. J. Clria, J.D. Kent, and M. Lopez-Parra Effects of celecoxib and naproxen on renal function in nonaziotemic patients with cirrhosis and ascites Hepatology 41 2005 579 587
49. E.A. Pariente, C. Bataille, E. Bercoff, and D. Lebrec Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites Gastroenterology 88 1985 1255 1259
50. P. Gentilini, R.G. Romanelli, and G. La Villla Effects of low-dose captopril on renal haemodynamics and function in patients with cirrhosis of the liver Gastroenterology 104 1993 588 594
51. A. Albillos, J.L. Lledo, and I. Rossi Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function Gastroenterology 109 1995 1257 1265
52. J. Llach, P. Gins, and V. Arroyo Effect of dipyridamole on kidney function in cirrhosis Hepatology 17 1993 59 64
53. J. Cabrera, V. Arroyo, and A.M. Ballesta Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage Gastroenterology 82 1982 97 105
54. H. Haupel, G.D. Bynum, E. Zamora, and H.B. El-Serag Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis Am J Gastroenterol 96 2001 2206 2210
55. M. Guevara, G. Fernández-Esparrach, and C. Alessandria Effects of contrast media on renal function in patients with cirrhosis: a prospective study Hepatology 40 2004 646 651
56. V. Arroyo, P. Gins, A.L. Gerbes, and F.J. Dudley Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 1996 164 176
57. F. Salerno, G. Borroni, P. Moser, S. Badalamenti, L. Cassara, and A. Maggi Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients Am J Gastroenterol 88 1993 514 519
58. J. Guardiola, C. Baliellas, X. Xiol, E.G. Fernandez, P. Gins, and P. Ventura External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites Am J Gastroenterol 97 2002 2374 2378
59. R. Moreau, P. Delegue, F. Pessione, S. Hillaire, F. Durand, and D. Lebrec Clinical characteristics and outcome of patients with cirrhosis and refractory ascites Liver Int 24 2004 457 464
60. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
61. F. Durand, and D. Valla Assessment of prognosis in cirrhosis Semin Liver Dis 28 2008 110 122
62. G.R. Silberhumer, H. Hetz, and S. Rasoul-Rockenschaub Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int 19 2006 275 281
63. J.G. O'Leary, R. Lepe, and G.L. Davis Indications for liver transplantation Gastroenterology 134 2008 1764 1766
64. W.R. Kim, S.W. Biggins, and W.K. Krmers Hyponatremia and mortality among patients on the liver transplant waiting list N Engl J Med 359 2008 1018 1026
65. A. Luca, B. Angermayr, and G. Bertolini An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis Liver Transpl 13 2007 1174 1180
66. K.P. Moore, and G.P. Aithal Guidelines on the management of ascites in cirrhosis Gut 55 2006 vi1 vi12
67. T.D. Boyer, and Z.J. Haskal The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension Hepatology 41 2005 386 400
68. A. Ochs, M. Rossle, K. Haag, K.H. Hauenstein, P. Deibert, and V. Siegerstetter The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites N Engl J Med 332 1995 1192 1197
69. F. Wong, K. Sniderman, P. Liu, Y. Allidina, M. Sherman, and L. Blendis Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites Ann Intern Med 122 1995 816 822
70. A.J. Sanyal, A.M. Freedman, V.A. Luketic, P.P. Purdum, M.L. Shiffman, and J. Demeo The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts Gastroenterology 112 1997 889 898
71. J. Quiroga, B. Sangro, M. Nunez, I. Bilbao, J. Longo, and L. Garcia-Villarreal Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters Hepatology 21 1995 986 994
72. L.A. Colombato, L. Spahr, J.P. Martinet, M.P. Dufresne, M. Lafortune, and D. Fenyves Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients Gut 39 1996 600 604
73. M. Huonker, Y.O. Schumacher, A. Ochs, S. Sorichter, J. Keul, and M. Rössle Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt Gut 44 1999 743 748
74. M. Merli, V. Valeriano, S. Funaro, A.F. Attili, A. Masini, and C. Efrati Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS) Am J Gastroenterol 97 2002 142 148
75. E. Lotterer, A. Wengert, and W.E. Fleig Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis Hepatology 29 1999 632 639
76. F. Wong, K. Sniderman, P. Liu, and L. Blendis The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt Gastroenterology 112 1997 899 907
77. M. Guevara, P. Gins, J.C. Bandi, R. Gilabert, P. Sort, and W. Jimenez Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems Hepatology 28 1998 416 422
78. A.L. Gerbes, V. Gulberg, T. Waggershauser, J. Holl, and M. Reiser Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites Hepatology 28 1998 683 688
79. M. Rössle, A. Ochs, V. Gulberg, V. Siegerstetter, J. Holl, and P. Deibert A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites N Engl J Med 342 2000 1701 1707
80. V. Gülberg, I. Liss, M. Bilzer, T. Waggershauser, M. Reiser, and A.L. Gerbes Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts Digestion 66 2002 127 130
81. M. Plauth, T. Schutz, and D.P. Buckendahl Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism J Hepatol 40 2004 228 233
82. M.S. Campbell, C.M. Brensinger, and A.J. Sanyal Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy Hepatology 42 2005 635 640
83. C. Gur, Y. Ilan, and O. Shibolet Hepatic hydrothorax: pathophysiology, diagnosis and treatment - review of the literature Liver Int 24 2004 281 284
84. F.D. Gordon, H.T. Anastopoulos, and W. Crenshaw The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt Hepatology 25 1997 1366 1369
85. V. Siegerstetter, P. Deibert, A. Ochs, M. Olschewski, H.E. Blum, and M. Rossle Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients Eur J Gastroenterol Hepatol 13 2001 529 534
86. J.Y. Wilputte, P. Goffette, F. Zech, A. Godoy-Gepert, and A. Geubel The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients Acta Gastroenterol Belg 70 2007 6 10
87. O. Riggio, S. Angeloni, F.M. Salvatori, A. De Santis, F. Cerini, and A. Farcomeni Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts Am J Gastroenterol 103 2008 2738 2746
88. M. Casado, J. Bosch, J.C. Garcia-Pagan, C. Bru, R. Bañares, and J.C. Bandi Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings Gastroenterology 114 1998 1296 1303 (Pubitemid 28243916)
89. D. Lebrec, N. Giuily, and A. Hadengue Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial J Hepatol 25 1996 135 144
90. P. Gins, J. Uriz, B. Calahorra, G. Garcia-Tsao, and E.T. AL Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis Gastroenterology 123 2002 1839 1847
91. A.J. Sanyal, C. Genning, and K.R. Reddy The North American study for the treatment of refractory ascites Gastroenterology 124 2003 634 641
92. F. Salerno, M. Merli, and O. Riggio Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites Hepatology 40 2004 629 635
93. A. Albillos, R. Bañares, M. Gonzalez, M.V. Catalina, and L.M. Molinero A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites J Hepatol 43 2005 990 996 (Pubitemid 41627984)
94. P. Deltenre, P. Mathurin, S. Dharancy, R. Moreau, P. Bulois, and J. Henrion Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis Liver Int 25 2005 349 356
95. G. D'Amico, A. Luca, A. Morabito, R. Miraglia, and M. D'Amico Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis Gastroenterology 129 2005 1282 1293 (Pubitemid 41446867)
96. S. Saab, J.M. Nieto, S.K. Lewis, and B.A. Runyon TIPS versus paracentesis for cirrhotic patients with refractory ascites Cochrane Database Syst Rev 2006 CD004889
97. F. Salerno, C. Camma, M. Enea, M. Rossle, and F. Wong Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data Gastroenterology 133 2007 825 834
98. V. Singh, P.C. Dheerendra, and B. Singh Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study Am J Gastroenterol 103 2008 1399 1405
99. P. Angeli, R. Volpin, and D. Piovan Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites Hepatology 28 1998 937 943
100. A. Krag, S. Møller, J.H. Henriksen, N.H. Holstein-Rathlou, F.S. Larsen, and F. Bendtsen Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome Hepatology 46 2007 1863 1871
101. P. Gins, F. Wong, M. Watson, L. Ruiz-Del-Arbol, A. Bilic, and D. Dobru Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia Hepatology 48 2008 204 213
102. P. Gins, F. Wong, H. Watson, R. Terg, R. Bruha, and P. Zarski Clinical trial: short term effects of combination of satavaptan, a selective vasopressin V receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia - a randomized, double blind, placebo controlled study Aliment Pharmacol Ther 31 2010 834 845
103. F. Wong, P. Gins, H. Watson, Y. Horsmans, P. Angeli, and P. Gow Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis J Hepatol 53 2010 283 290
104. F. Wong, M. Bernardi, Y. Horsmans, Z. Cabrijan, H. Watson, and P. Gins Effects of satavaptan, an oral vasopressin V2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long-term, placebo-controlled study J Hepatol 50 2009 S42 S43
105. W.R. Caly, and E. Strauss A prospective study of bacterial infections in patients with cirrhosis J Hepatol 18 1993 353 358
106. J. Fernández, M. Navasa, J. Gómez, J. Colmenero, J. Vila, and V. Arroyo Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis Hepatology 35 2002 140 148
107. F. Wong, M. Bernardi, R. Balk, B. Christman, R. Moreau, and G. Garcia-Tsao Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club Gut 54 2005 718 725
108. G. Garcia-Tsao Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis Gastroenterology 120 2001 726 748
109. J.B. Nousbaum, J.F. Cadranel, P. Nahon, E. Nguyen Khac, R. Moreau, and T. Thévenot Diagnostic accuracy of the Multistix 8 SG® reagent strip in diagnosis of spontaneous bacterial peritonitis Hepatology 45 2007 1275 1281
110. L.T. Evans, W.R. Kim, J.J. Poterucha, and P.S. Kamath Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites Hepatology 37 2003 897 901
111. A. Plessier, M.A. Denninger, Y. Consigny, F. Pessione, C. Francoz, and F. Durand Coagulation disorders in patients with cirrhosis and severe sepsis Liver Int 23 2003 440 448
112. C. Guarner, and G. Soriano Spontaneous bacterial peritonitis Semin Liver Dis 17 1997 203 217
113. S. Angeloni, G. Nicolini, M. Merli, F. Nicolao, G. Pinto, and T. Aronne Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis Am J Gastroenterol 98 2003 1844 1848
114. E. Nguyen Khac, J.F. Cadranel, T. Thévenot, and J.B. Nousbaum Review article: utility of reagent strips in diagnosis of infected ascites in cirrhotic patients Aliment Pharmacol Ther 28 2008 282 288
115. B.A. Runyon, and J.C. Hoefs Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis Hepatology 4 1984 1209 1211
116. R. Terg, D. Levi, P. Lopez, C. Rafaelli, S. Rojter, and R. Abecasis Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease Dig Dis Sci 37 1992 1499 1504
117. X. Xiol, J.M. Castellví, J. Guardiola, E. Sesé, J. Castellote, and A. Perelló Spontaneous bacterial empyema in cirrhotic patients: a prospective study Hepatology 23 1996 719 723
118. J. Felisart, A. Rimola, V. Arroyo, R.M. Pérez-Ayuso, E. Quintero, and P. Gins Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections Hepatology 5 1985 457 462
119. A. Rimola, J.M. Salmerón, G. Clemente, L. Rodrigo, A. Obrador, and M.L. Miranda Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study Hepatology 21 1995 674 679
120. M. Navasa, A. Follo, J.M. Llovet, G. Clemente, V. Vargas, and A. Rimola Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis Gastroenterology 111 1996 1011 1017
121. P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, and L. Ruiz del Arbol Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med 341 1999 403 409
122. E. Ricart, G. Soriano, M.T. Novella, J. Ortiz, M. Sbat, and L. Kolle Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients J Hepatol 32 2000 596 602
123. B.A. Runyon, J.G. McHutchison, M.R. Antillon, E.A. Akriviadis, and A.A. Montano Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients Gastroenterology 100 1991 1737 1742
124. R. Terg, S. Cobas, E. Fassio, G. Landeira, B. Ríos, and W. Vasen Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study J Hepatol 33 2000 564 569
125. P. Angeli, S. Guarda, S. Fasolato, E. Miola, R. Craighero, and F. Piccolo Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost Aliment Pharmacol Ther 23 2006 75 84
126. A. Follo, J.M. Llovet, M. Navasa, R. Planas, X. Forns, and A. Francitorra Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis Hepatology 20 1994 1495 1501
127. S. Fasolato, P. Angeli, L. Dallagnese, G. Maresio, E. Zola, and E. Mazza Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features Hepatology 45 2007 223 229
128. M. Navasa, A. Follo, X. Filella, W. Jiménez, A. Francitorra, and R. Planas Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality Hepatology 27 1998 1227 1232
129. S.H. Sigal, C.M. Stanca, J. Fernandez, V. Arroyo, and M. Navasa Restricted use of albumin for spontaneous bacterial peritonitis Gut 56 2007 597 599
130. R. Terg, A. Gadano, M. Cartier, P. Casciato, R. Lucero, and A. Muñoz Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study Liver Int 29 2009 415 419
131. J. Fernández, J. Monteagudo, X. Bargallo, W. Jiménez, J. Bosch, and V. Arroyo A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis Hepatology 42 2005 627 634
132. A. Rimola, F. Bory, J. Teres, R.M. Pérez-Ayuso, V. Arroyo, and J. Rodés Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage Hepatology 5 1985 463 467
133. G. Bleichner, R. Boulanger, P. Squara, J.P. Sollet, and A. Parent Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage Br J Surg 73 1986 724 726
134. G. Soriano, C. Guarner, A. Tomas, C. Villanueva, X. Torras, and D. González Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage Gastroenterology 103 1992 1267 1272
135. M. Blaise, D. Pateron, J.C. Trinchet, S. Levacher, M. Beaugrand, and J.L. Porriat Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage Hepatology 20 1994 34 38
136. B. Bernard, J.F. Cadranel, D. Valla, S. Escolano, V. Jarlier, and P. Opolon Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study Gastroenterology 108 1995 1828 1834
137. A. Pauwels, N. Mostefa-Kara, B. Debenes, E. Degoutte, and V.G. Levy Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection Hepatology 24 1996 802 806
138. M. Deschenes, and J.P. Villeneuve Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis Am J Gastroenterol 94 1999 2193 2197
139. B. Bernard, J.D. Grange, E.N. Khac, X. Amiot, P. Opolon, and T. Poynard Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis Hepatology 29 1999 1655 1661
140. W.J. Hsieh, H.C. Lin, S.J. Hwang, M.C. Hou, F.Y. Lee, and F.Y. Chang The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding Am J Gastroenterol 93 1998 962 966
141. M.C. Hou, H.C. Lin, T.T. Liu, B.I. Kuo, F.Y. Lee, and F.Y. Chang Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial Hepatology 39 2004 746 753
142. J. Goulis, A. Armonis, D. Patch, C. Sabin, L. Greenslade, and A.K. Burroughs Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage Hepatology 27 1998 1207 1212
143. S. Vivas, M. Rodríguez, M.A. Palacio, A. Linares, J.L. Alonso, and L. Rodrigo Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding Dig Dis Sci 46 2001 2752 2757
144. K. Soares-Weiser, M. Brezis, R. Tur-Kaspa, and L. Leibovici Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding Cochrane Database Syst Rev 2002 CD002907
145. N. Carbonell, A. Pauwels, L. Serfaty, O. Fourdan, V.G. Lévy, and R. Poupon Improved survival after variceal bleeding in patients with cirrhosis over the past two decades Hepatology 40 2004 652 659
146. C. Dupeyron, N. Mangeney, L. Sedrati, B. Campillo, P. Fouet, and G. Leluan Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis Antimicrob Agents Chemother 38 1994 340 344
147. J.R. Aparicio, J. Such, S. Pascual, A. Arroyo, J. Plazas, and E. Girona Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences J Hepatol 31 1999 277 283
148. J. Fernández, L. Ruiz del Arbol, C. Gómez, R. Durandez, R. Serradilla, and C. Guarner Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage Gastroenterology 131 2006 1049 1056
149. B.A. Runyon Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis Gastroenterology 91 1986 1343 1346
150. M. Andreu, R. Solá, A. Sitges-Serra, C. Alia, M. Gallen, and M.C. Vila Risk factors for spontaneous bacterial peritonitis Gastroenterology 104 1993 1133 1138
151. J. Llach, A. Rimola, M. Navasa, P. Gins, J.M. Salmerón, and A. Gins Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration Hepatology 16 1992 724 727
152. C. Guarner, R. Sol, G. Soriano, M. Andreu, M.T. Novella, and C. Vila Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels Gastroenterology 117 1999 414 419
153. G. Soriano, C. Guarner, M. Teixidó, J. Such, J. Barrios, and J. Enríquez Selective intestinal decontamination prevents spontaneous bacterial peritonitis Gastroenterology 100 1991 477 481
154. M. Novella, R. Sol, G. Soriano, M. Andreu, J. Gana, and J. Ortiz Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin Hepatology 25 1997 532 536
155. J.D. Grange, D. Roulot, G. Pelletier, E.A. Pariente, J. Denis, and O. Ink Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial J Hepatol 29 1998 430 436
156. J. Fernández, M. Navasa, R. Planas, S. Montoliu, D. Monfort, and G. Soriano Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology 133 2007 818 824
157. R. Terg, E. Fassio, M. Guevara, M. Cartier, C. Longo, and R. Lucero Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study J Hepatol 48 2008 774 779
158. P. Gins, A. Rimola, R. Planas, V. Vargas, F. Marco, and M. Almela Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial Hepatology 12 1990 716 724
159. T.M. Bauer, A. Follo, M. Navasa, J. Vila, R. Planas, and G. Clemente Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence Dig Dis Sci 47 2002 1356 1361
160. A. Rolachon, L. Cordier, Y. Bacq, J.B. Nousbaum, A. Franza, and J.C. Paris Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial Hepatology 22 1995 1171 1174
161. N. Singh, T. Gayowski, V.L. Yu, and M.M. Wagener Trimethoprim- sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial Ann Intern Med 122 1995 595 598
162. B. Campillo, C. Dupeyron, J.P. Richardet, N. Mangeney, and G. Leluan Epidemiology of severe hospital acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin Clin Infect Dis 26 1998 1066 1070
163. P. Gins, T. Berl, and M. Bernardi Hyponatremia in cirrhosis: from pathogenesis to treatment Hepatology 28 1998 851 864
164. V. Arroyo, J. Clria, J. Saló, and W. Jiménez Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites Semin Liver Dis 6 1986 353 369
165. Ginès P, Cárdenas A, Schrier RW. Liver disease and the kidney. In: Schrier Robert W, editor. Diseases of the kidney & urinary tract. 8th ed., vol. III. Lippincott Williams & Wilkins; p. 2179-2205.
166. P. Angeli, F. Wong, H. Watson, and P. Gines Hyponatremia in cirrhosis: results of a patient population survey Hepatology 44 2006 1535 1542
167. Hyponatremia treatment guidelines 2007 Expert panel recommendations Am J Med 120 2007 S1 S21
168. V. Arroyo, J. Rodés, M.A. Gutiérrez-Lizárraga, and L. Revert Prognostic value of spontaneous hyponatremia in cirrhosis with ascites Am J Dig Dis 21 1976 249 256
169. R.L. Cosby, B. Yee, and R.W. Schrier New classification with prognostic value in cirrhotic patients Miner Electrolyte Metab 15 1989 261 266
170. A. Porcel, F. Diaz, P. Rendón, M. Macias, L. Martín- Herrera, and J.A. Girón-González Dilutional hyponatremia in patients with cirrhosis and ascites Arch Intern Med 162 2002 323 328
171. S. Biggins, H.J. Rodriguez, P. Bachetti, N.M. Bass, J.P. Robert, and N.A. Terrault Serum sodium predicts mortality in patients listed for liver transplantation Hepatology 41 2005 32 39
172. A.E. Ruf, W.K. Kremers, L.L. Chavez, V.I. Descalzi, L.G. Podesta, and F.G. Villamil Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone Liver Transpl 11 2005 336 343
173. S.W. Biggins, W.R. Kim, and N.A. Terrault Evidence-based incorporation of serum sodium concentration into MELD Gastroenterology 130 2006 1652 1660
174. M.C. Londoño, A. Cardenas, and M. Guevara MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation Gut 56 2007 1283 1290
175. M.C. Londoño, M. Guevara, and A. Rimola Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation Gastroenterology 130 2006 1135 1143
176. M.F. Dawas, J.D. Lewsey, and J. Neuberger The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study Liver Transpl 13 2007 1115 1124
177. B.C. Yun, W.R. Kim, J.T. Benson, S.W. Biggins, T.M. Therneau, and W.K. Kremers Impact of pretransplant hyponatremia on outcome following liver transplantation Hepatology 49 2009 1610 1615
178. P.A. McCormick, P. Mistry, G. Kaye, A.K. Burroughs, and N. McIntyre Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites Gut 31 1990 204 207
179. R. Jalan, R. Mookerjee, L. Cheshire, and R. Williams Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trail J Hepatol 46 2007 232A [Abstract]
180. A. Troyer, W. Pilloy, I. Broeckaert, and J.C. Demanet Demeclocycline treatment of water retention in cirrhosis Ann Intern Med 85 1976 336 337
181. R.M. Pérez-Ayuso, V. Arroyo, J. Camps, W. Jiménez, M. Rodamilans, and A. Rimola Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics Nephron 36 1984 30 37
182. F. Carrilho, J. Bosch, V. Arroyo, A. Mas, J. Viver, and J. Rodés Renal failure associated with demeclocycline in cirrhosis Ann Intern Med 87 1977 195 197
183. A. Gadano, R. Moreau, F. Pessione, C. Trombino, N. Giuily, and P. Sinnassamy Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis J Hepatol 32 2000 38 42
184. F. Quittnat, and P. Gross Vaptans and the treatment of water-retaining disorders Semin Nephrol 26 2006 234 243
185. P. Gins The vaptans: a promising therapy in the management of advanced cirrhosis J Hepatol 46 2007 1150 1152
186. G. Decaux, A. Soupart, and G. Vassart Non-peptide arginine-vasopressin antagonists: the vaptans Lancet 371 2008 1624 1632
187. R.W. Schrier, P. Gross, M. Gheorghiade, T. Berl, J.G. Verbalis, and F.S. Czerwiec Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
188. N. Afdhal, A. Cardenas, and P. Gins Randomized, placebo-controlled trial of tolvaptan, a novel V2-receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis Hepatology 42 2005 LB19A [Abstract]
189. J.G. O'Leary, and G. Favis Conivaptan increases serum sodium in hyponatremic patients with end stage liver disease Liver Transpl 15 2009 1325 1329
190. A. Gerbes, V. Gülberg, P. Gins The VPA Study Group Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial Gastroenterology 124 2003 933 939
191. F. Wong, A.T. Blei, L.M. Blendis, and P.J. Thuluvath A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial Hepatology 37 2003 182 191
192. F. Salerno, A. Gerbes, P. Gins, F. Wong, and V. Arroyo Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis Gut 56 2007 1310 1318 (Pubitemid 47300435)
193. R. Bellomo, C. Ronco, and J.A. Kellum Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group Crit Care 8 2004 R204 R212
194. V. Stadlbauer, G.A. Wright, and M. Banaji Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis Gastroenterology 134 2008 111 119
195. P. Gins, and R.W. Schrier Renal failure in cirrhosis N Engl J Med 361 2009 1279 1290
196. L. Dagher, and K. Moore The hepatorenal syndrome Gut 19 2001 729 737
197. D. Thabut, J. Massard, A. Gangloff, N. Carbonell, C. Francoz, and E. Nguyen-Khac Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure Hepatology 46 2007 1872 1882
198. C. Terra, M. Guevara, A. Torre, R. Gilabert, J. Fernández, and M. Martín-Llahí Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score Gastroenterology 129 2005 1944 1953
199. A. Gins, A. Escorsell, P. Gins, J. Saló, W. Jiménez, and L. Inglada Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology 105 1993 229 236
200. C. Alessandria, O. Ozdogan, M. Guevara, T. Restuccia, W. Jiménez, and V. Arroyo MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation Hepatology 41 2005 1282 1289
201. M.C. Kew, R.R. Varma, D.J. Sampson, and S. Sherlock The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver Gut 13 1972 293 296
202. K. Lenz, H. Hörtnagl, W. Druml, H. Reither, R. Schmid, and B. Schneeweiss Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor Gastroenterology 101 1991 1060 1067
203. M. Guevara, P. Gins, and G. Fernández-Esparrach Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1998 35 41
204. V. Gülberg, M. Bilzer, and A.L. Gerbes Long term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine Hepatology 30 1999 870 875
205. R. Moreau, F. Durand, and T. Poynard Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study Gastroenterology 122 2002 923 930
206. F. Fabrizi, V. Dixit, and P. Martin Metaanalysis: terlipressin therapy for hepatorenal syndrome Aliment Pharmacol Ther 24 2006 935 944
207. L.L. Gluud, M.S. Kjaer, and E. Christensen Terlipressin for hepatorenal syndrome Cochrane Database Syst Rev 4 2006 CD005162
208. A.J. Sanyal, T. Boyer, and G. Garcia-Tsao A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome Gastroenterology 134 2008 1360 1368
209. L. Martin, M. Lahi, M.N. Pepin, and M. Guevara Terlipressin and albúmina vs albúmina in patients with cirrhosis and hepatorenal syndrome: a randomized study Gastroenterology 134 2008 1352 1359
210. R. Moreau, and D. Lebrec The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond Hepatology 43 2006 385 394
211. P. Gins, and M. Guevara Therapy with vasoconstrictor drugs in cirrhosis: the time has arrived Hepatology 46 2007 1685 1687
212. A. Nazar, G.H. Pereira, M. Guevara, M. Martin-Llahí, and M.N. Pepin Predictors of response to therapy to terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 51 2010 219 226
213. R. Ortega, P. Gins, and J. Uriz Terlipressin therapy with and without albúmina for patients with hepatorenal syndrome: results of a prospective, nonrandomized study Hepatology 36 2002 941 948
214. L.L. Gluud, K. Christensen, E. Christensen, and A. Krag Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome Hepatology 51 2010 576 584
215. C. Alessandria, W.D. Venon, A. Marzano, C. Barletti, M. Fadda, and M. Rizzetto Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2 Eur J Gastroenterol Hepatol 47 2002 401 404
216. P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner, and R. Merenda Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1999 1690 1697
217. F. Wong, L. Pantea, and K. Sniderman Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 40 2004 55 64
218. C. Duvoux, D. Zanditenas, C. Hézode, A. Chauvat, J.L. Monin, and F. Roudot-Thoraval Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study Hepatology 36 2002 374 380
219. E. Akriviadis, R. Bortla, W. Briggs, S. Han, T. Reynolds, and O. Shakil Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial Gastroenterology 119 2000 1637 1648
220. D. Lebrec, D. Thabut, F. Oberti, J.M. Perarnau, B. Condat, and H. Barraud Pentoxifylline does not decrease short term mortality but does reduce complications in patients with advanced cirrhosis Gastroenterology 138 2010 1755 1762
221. K.A. Brensing, J. Textor, J. Perz, P. Schiedermaier, P. Raab, and H. Strunk Long-term outcome after transjugular intrahepatic portosystemic-stent shunt in non-transplant cirrhotics with hepatorena syndrome: a phase II study Gut 47 2000 288 295
222. F. Keller, H. Heinze, F. Jochimson, J. Passfall, D. Schuppan, and P. Büttner Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis Ren Fail 17 1995 135 146
223. R.K. Capling, and B. Bastani The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis Ren Fail 26 2004 563 568
224. S.R. Mitzner, J. Stange, S. Klammt, T. Risler, C.M. Erley, and B.D. Bader Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial Liver Transpl 6 2000 287 289
225. W. Laleman, A. Wilmer, P. Evenepoel, I.V. Elst, M. Seegers, and Z. Zaman Crit Care 10 2006 R108
226. T.A. Gonwa, C.A. Morris, R.M. Goldstein, B.S. Husberg, and G.B. Klintmalm Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients Transplantation 51 1991 428 430
227. D.R. Jeyarajah, T.A. Gonwa, and M. McBride Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant Transplantation 64 1997 1760 1765
228. M.R. Charlton, W.J. Wall, A.O. Ojo, P. Gins, S. Textor, and F.S. Shihab International liver transplantation expert panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation Liver Transpl 15 2009 S1 S34
229. T. Restuccia, R. Ortega, M. Guevara, P. Gins, C. Alessandria, and O. Ozdogan Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study J Hepatol 40 2004 140 146